FDA
-
-
-
-
-
-
-
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
-
-
-
-
-
-
-
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
-
-
-
-
-
-
-
Selecta Biosciences (SELB) Announces Appointment of Blaine Davis as Chief Financial Officer
-
-
-
-
-
-
-
Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates
-
-
-
-
-
-
-
Selecta Biosciences (SELB) Announces Top Line Data from Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR in Gene Therapy
-
-
-
-
-
-
-
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
-
-
-
-
-
-
-
Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

